Dr. Gina Keiffer, MD
Claim this profileSidney Kimmel Cancer Center at Thomas Jefferson University
Studies T-Lymphoblastic Leukemia/Lymphoma
Studies Myeloid Leukemia
7 reported clinical trials
16 drugs studied
Area of expertise
1T-Lymphoblastic Leukemia/Lymphoma
13q positive
13q negative
12 positive
2Myeloid Leukemia
FLT3 positive
NPM1 positive
KMT2A (MLL)-fusion positive
Affiliated Hospitals
Clinical Trials Gina Keiffer, MD is currently running
Chemotherapy + Enzyme Inhibitors
for Acute Myeloid Leukemia
This phase I trial tests the safety, side effects, and best dose of palbociclib or tazemetostat in combination with CPX-351 in treating patients with acute myeloid leukemia (AML) that has come back (relapsed) or does not respond to treatment (refractory). CPX-351 is a combination of the chemotherapy drugs, daunorubicin and cytarabine, which is the standard of care for AML. Chemotherapy drugs work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Palbociclib and tazemetostat are enzyme inhibitor drugs that are approved for treating certain cancers but not AML. These drugs may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving CPX-351 chemotherapy with enzyme inhibitors palbociclib or tazemetostat may kill more cancer cells.
Recruiting1 award Phase 1
DSP-5336
for Leukemia
This trial is testing a new drug called DSP 5336 to help treat adults with certain types of blood cancer that have come back or didn't respond to previous treatments. The study will first find the best amount to give and then check how safe and helpful it is.
Recruiting1 award Phase 1 & 215 criteria
More about Gina Keiffer, MD
Clinical Trial Related1 year of experience running clinical trials · Led 7 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Gina Keiffer, MD has experience with
- Venetoclax
- Liposome-encapsulated Daunorubicin-Cytarabine
- Palbociclib
- Tazemetostat
- Decitabine
- Navitoclax
Breakdown of trials Gina Keiffer, MD has run
T-Lymphoblastic Leukemia/Lymphoma
Myeloid Leukemia
Acute Myeloid Leukemia
Lymphoid Leukemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Gina Keiffer, MD specialize in?
Gina Keiffer, MD focuses on T-Lymphoblastic Leukemia/Lymphoma and Myeloid Leukemia. In particular, much of their work with T-Lymphoblastic Leukemia/Lymphoma has involved 13q positive patients, or patients who are 13q negative.
Is Gina Keiffer, MD currently recruiting for clinical trials?
Yes, Gina Keiffer, MD is currently recruiting for 4 clinical trials in Philadelphia Pennsylvania. If you're interested in participating, you should apply.
Are there any treatments that Gina Keiffer, MD has studied deeply?
Yes, Gina Keiffer, MD has studied treatments such as Venetoclax, Liposome-encapsulated Daunorubicin-Cytarabine, Palbociclib.
What is the best way to schedule an appointment with Gina Keiffer, MD?
Apply for one of the trials that Gina Keiffer, MD is conducting.
What is the office address of Gina Keiffer, MD?
The office of Gina Keiffer, MD is located at: Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania 19107 United States. This is the address for their practice at the Sidney Kimmel Cancer Center at Thomas Jefferson University.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.